WallStreetZenWallStreetZen

NASDAQ: AMPH
Amphastar Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Amphastar Pharmaceuticals earnings were $141.6M for the trailing 12 months ending Mar 31, 2025, with -8.8% growth year over year. The latest AMPH earnings report on Mar 31, 2025 announced Q1 2025 earnings of $25.3M, down 33.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AMPH reported annual earnings of $159.5M, with 16% growth.

AMPH past earnings growth

How has AMPH's earnings growth performed historically?

Company
-8.75%
Industry
1.37%
Market
34.53%
AMPH's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AMPH's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
AMPH's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

AMPH earnings history

Current Revenue
$730.7M
Current Earnings
$141.6M
Current Profit Margin
19.4%

AMPH Return on Equity

Current Company
19.4%
Current Industry
12.8%
Current Market
31.4%
AMPH's Return on Equity (19.4%)... subscribe to Premium to read more.
High Return on Equity Performance

AMPH undefined

Current Company
9.1%
Current Industry
6.9%
AMPH is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AMPH announces earnings.

AMPH undefined

Current Company
14.07%
Current Industry
14.3%
AMPH's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AMPH vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AMPH$265.38M$141.63M+21.34%$2.92
PCRX$31.32M-$103.73MN/A-$2.25
HROW$18.65M-$21.70MN/A-$0.61
PAHC$123.68M$31.79M-2.36%$0.79
DVAX-$40.59M-$60.07MN/A-$0.49
View Top Pharmaceutical Stocks

Amphastar Pharmaceuticals Earnings Reports & History FAQ

What were Amphastar Pharmaceuticals's earnings last quarter?

On AMPH's earnings call on Invalid Date, Amphastar Pharmaceuticals (NASDAQ: AMPH) reported Q1 2025 earnings per share (EPS) of $0.53, up 41.11% year over year. Total AMPH earnings for the quarter were $25.29 million. In the same quarter last year, Amphastar Pharmaceuticals's earnings per share (EPS) was $0.90.

If you're new to stock investing, here's how to buy Amphastar Pharmaceuticals stock.

Is Amphastar Pharmaceuticals profitable or losing money?

As of the last Amphastar Pharmaceuticals earnings report, Amphastar Pharmaceuticals is currently profitable. Amphastar Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $141.63 million, a 8.44% decrease year over year.

What was AMPH's earnings growth in the past year?

As of Amphastar Pharmaceuticals's earnings date in Invalid Date, Amphastar Pharmaceuticals's earnings has grown -8.75% year over year. This is 10.12 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 1.37%. AMPH earnings in the past year totalled $141.63 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.